The present application describes modulators of MIP-1.alpha. of formula (I): ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R.sub.1, R.sub.4, R.sub.5, R.sub.5a and R.sub.5b are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.